Literature DB >> 6857245

Urinary phenyl acetate: a diagnostic test for depression?

H C Sabelli, J Fawcett, F Gusovsky, J Javaid, J Edwards, H Jeffriess.   

Abstract

The compound 2-phenylethylamine is an "endogenous amphetamine" which may modulate central adrenergic functions. 2-Phenylethylamine is mainly metabolized by monoamine oxidase to form phenyl acetate (PAA). The 24-hour urinary excretion of PAA was measured in normal healthy volunteers and depressed patients. Patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, edition 3. In 70 percent of healthy volunteers of both sexes, the excretion of PAA ranged between 70 and 175 milligrams per 24 hours (mean = 141.1 +/- 10.2). Inpatients with major depressive disorder (unipolar type) (N = 31) excreted less PAA (68.7 +/- 7.0 milligrams per 24 hours) and 55 percent of them excreted less than 70 milligrams per 24 hours; there were no significant differences in the PAA excretion between untreated patients (N = 13) and those treated with antidepressants that were not effective (N = 18). The PAA excretion was reduced to a lesser extent in 35 less severely depressed unipolar outpatients (drug-free for 1 week) (86.3 +/- 11.8 milligrams per 24 hours). These results suggest that low PAA urinary excretion may be a reliable state marker for the diagnosis of some forms of unipolar major depressive disorders.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6857245     DOI: 10.1126/science.6857245

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  10 in total

1.  New high-performance liquid chromatographic procedure for the detection and quantification of beta-phenylethylamine.

Authors:  F Gusovsky; K A Jacobson; K L Kirk; T Marshall; M Linnoila
Journal:  J Chromatogr       Date:  1987-03-20

2.  Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression.

Authors:  Edana Cassol; Vikas Misra; Susan Morgello; Gregory D Kirk; Shruti H Mehta; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

3.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

4.  Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.

Authors:  S H Kennedy; B A Davis; G M Brown; C G Ford; J d'Souza
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

5.  Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS.

Authors:  J Lauber; P C Waldmeier
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

6.  Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.

Authors:  B A Davis; S H Kennedy; J D'Souza; D A Durden; D S Goldbloom; A A Boulton
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

7.  Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of myasthenia gravis and rheumatoid arthritis.

Authors:  Derrick Blackmore; Liang Li; Nan Wang; Walter Maksymowych; Elaine Yacyshyn; Zaeem A Siddiqi
Journal:  Metabolomics       Date:  2020-01-04       Impact factor: 4.290

8.  Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations.

Authors:  Jacopo Troisi; Luca Pierri; Annamaria Landolfi; Francesca Marciano; Antonella Bisogno; Federica Belmonte; Carmen Palladino; Salvatore Guercio Nuzio; Pietro Campiglia; Pietro Vajro
Journal:  Nutrients       Date:  2017-05-11       Impact factor: 5.717

9.  Quantification of Gut Microbiota Dysbiosis-Related Organic Acids in Human Urine Using LC-MS/MS.

Authors:  Yu-Tsung Lee; Sui-Qing Huang; Ching-Hao Lin; Li-Heng Pao; Chun-Hui Chiu
Journal:  Molecules       Date:  2022-08-23       Impact factor: 4.927

10.  Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.